--- title: "Solid Biosciences updates resale prospectus to add selling stockholders" url: "https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-05" section: "Financings" tickers: "NASDAQ:SLDB" source: "https://www.sec.gov/Archives/edgar/data/1707502/000119312526259503/d149984d424b7.htm" summary: "Solid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in" --- By the aibio.space news desk. Sources - [Solid Biosciences Inc. 424B7 (2026-06-05)](https://www.sec.gov/Archives/edgar/data/1707502/000119312526259503/d149984d424b7.htm) - [Solid Biosciences Inc. 10-K (2026-03-19): business](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/sldb-20251231.htm) - [Solid Biosciences Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) [SLDB](https://aibio.space/companies/solid-biosciences/) 2026-06-05 # Solid Biosciences updates resale prospectus to add selling stockholders Tickers [SLDB](https://aibio.space/companies/solid-biosciences/) Solid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell. ## Key facts - **Company**: Solid Biosciences Inc. (NASDAQ: SLDB) - **News type**: Financings - **Primary source**: [Solid Biosciences Inc. 424B7 (2026-06-05)](https://www.sec.gov/Archives/edgar/data/1707502/000119312526259503/d149984d424b7.htm) *A trading board being updated by hand. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.* Solid Biosciences Inc. filed a prospectus supplement on June 5, 2026 under Rule 424(b)(7). The supplement updates a resale prospectus dated March 31, 2026, which forms part of the company's Form S-3 registration statement, No. 333-294460. Its only purpose is to add selling stockholders who have acquired shares from holders already named in the prospectus. The company says the aggregate number of shares registered under the prospectus has not changed. The shares trade on the Nasdaq Global Select Market under the symbol SLDB. ## The table The table is as of May 15, 2026, when 98,449,606 common shares were outstanding. Perceptive Life Sciences Master Fund holds 11,969,078 shares, or 12.15%, before the offering. It is offering 8,912,655 shares, which the footnotes say are underlying pre-funded warrants issued in the March private placement. The footnotes also say Perceptive is prohibited from exercising those warrants if it would then own more than 9.99% of the common stock outstanding. Its figure includes 62,432 shares underlying options held by Adam Stone, a member of the company's board of directors. The footnotes say the table counts shares that may be acquired on exercise of pre-funded warrants without giving effect to the beneficial ownership limitation. RA Capital Management entities are offering 4,456,327 shares and would hold 10,400,701 after, or 9.99%. Bain Capital Life Sciences entities are offering 5,347,593 shares and would hold 10,950,092 after, or 9.93%. Several holders are offering their entire position. Deep Track Biotechnology Master Fund offers 3,565,062 shares and shows no shares after the offering. Entities affiliated with Janus Henderson Investors offer 4,010,695 shares with none left. SILV Fund offers 1,247,771 shares with none left, and Fidelity Advisor Biotechnology Fund offers 677,565 shares with none left. Woodline Master Fund offers 178,253 shares and shows none after. Entities affiliated with Redmile Group, LLC offer 178,253 shares and would hold 1,833,642 after. The footnotes say the company does not know when or in what amounts any selling stockholder may offer and sell. The supplement does not give prices for the resales, and it does not say what the holders will receive. ## The March placement The shares and pre-funded warrants in the table were issued in the company's private placement, and the footnotes say pre-funded warrants for 4,456,327 shares were issued to an RA Capital fund in it. Several of the holders in this table are among the investors that took part, including Perceptive, Janus Henderson, RA Capital, Vestal Point and Deep Track. ## The company's losses The company's annual report, filed March 19, 2026, shows research and development expense of $140.3 million in 2025, up from $96.4 million in 2024. Cash used in operations was $156.3 million in 2025, against $100.0 million in 2024. ## What the business is The annual report describes a pipeline of neuromuscular candidates, including SGT-003 and SGT-212, and cardiac candidates, including SGT-401, SGT-501 and SGT-601. Its forward-looking statements name the timing of regulatory approval, pricing and reimbursement, and market acceptance as uncertainties for those candidates. They also list the company's ability to establish sales, marketing and distribution capabilities, and its ability to maintain collaborations, as factors that could affect results. ## What the supplement leaves out The supplement does not say whether the resales have started or what price the new holders paid to the existing holders. It also does not name the existing selling stockholders who sold to the newly added holders, beyond the statement that the new holders acquired shares from them. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SLDB Solid Biosciences Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Solid Biosciences updates resale prospectus to add selling stockholders", 2026-06-05, https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/